- About ELS
- Therapeutic Areas
- Operational Metrics
- Contact Us
With its large and growing population, India has developed significant prevalence of neurological and psychiatric diseases and disorders. Statistics show that in India there are more than 10 million cases of neuropsychiatric conditions currently being treated. The World Health Organization (WHO) estimates that a minimum of 25 million people in India are in need of mental health services.
The rising rates of dementia, TBI and stroke will potentially add over 3.5 million people to the disabled population, annually. The condition with the greatest prevalence in India is Epilepsy. In addition there are approximately 10 million cases of other neuropsychiatric conditions including Stroke, TIA, Parkinson’s Disease, Vascular Dementia, Alzheimer’s Dementia, Migraine, Epilepsy, Cluster Headache, Neuropathies – Diabetic & Non diabetic, Brain tumors, Multiple Sclerosis, Meningitis, MDD, and Schizophrenia.
Dementia. The second contributor to the emerging epidemic is dementia. The Indian population is aging rapidly, with the proportion of older adults in India predicted to increase from 76 million to 301 million by 2051. Traumatic Brain Injury (TBI). It is estimated that 1 million persons are disabled due to TBI annually. Stroke with incidence doubled, the incidence rate of stroke in India is currently estimated to be 145 per 1,00,000 people.
Our access to the most prominent Neuropsychiatry sites and Investigators ensures a large and diverse patient pool and leading lines of medical treatment. Using our internal databases and epidemiology intelligence we can quickly determine if India is the right fit for your study. In addition, ELS can quickly mobilize a team of experienced project managers to conduct a study feasibility analysis and determine the appropriate sites and availability of patients.
We ensure that neurological clinical trials are conducted according to ICH-GCP guidelines and meet the highest standards of ethics and integrity.